Lento Bio was formed in 2022 in collaboration with Ichor Life Sciences and Clarkson University’s Shipley Center for Innovation, with the goal to develop effective, safe, and durable treatments for chronic age-related disease by using small molecules to directly target molecular damage. Our primary focus is the removal of Advanced Glycation EndProducts (AGEs), initially focusing on damage to the lens in presbyopia while also exploring further opportunities in systemic disease.

Lento Bio

Org chart

Similar companies